PortalPublikationenThe failure of cetuximab-based de-intensified regimes for HP...

The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective

Standard

The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective. / Rieckmann, Thorsten; Kriegs, Malte.

in: CLIN TRANSL RAD ONCO, Jahrgang 17, 07.2019, S. 47-50.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Rieckmann, T & Kriegs, M 2019, 'The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective', CLIN TRANSL RAD ONCO, Jg. 17, S. 47-50. https://doi.org/10.1016/j.ctro.2019.05.003

APA

Rieckmann, T., & Kriegs, M. (2019). The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective. CLIN TRANSL RAD ONCO, 17, 47-50. https://doi.org/10.1016/j.ctro.2019.05.003

Vancouver

Rieckmann T, Kriegs M. The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective. CLIN TRANSL RAD ONCO. 2019 Jul;17:47-50. https://doi.org/10.1016/j.ctro.2019.05.003

Bibtex

@article{fa465b89bec44bce9822693f1995e835,
title = "The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective",
abstract = "Human Papillomavirus-positive oropharyngeal cancer is a rising tumor entity with unique characteristics and favorable prognosis. Because current multimodal therapies are associated with severe toxicity, different strategies for treatment de-intensification are being tested in clinical trials. In this context two phase 3 studies, which examined the potential of the monoclonal anti-EGFR antibody cetuximab to replace concomitant cisplatin-based chemotherapy, have concordantly reported inferiority of this de-intensification approach. In this opinion article we discuss these recent negative results in the light of previous clinical and preclinical research on the combination of EGFR-inhibition and irradiation. Collectively these data question the effectiveness of EGFR-inhibition in the curative treatment of both HPV-positive and HPV-negative head and neck cancer but provide guidance for future translational research.",
author = "Thorsten Rieckmann and Malte Kriegs",
year = "2019",
month = jul,
doi = "10.1016/j.ctro.2019.05.003",
language = "English",
volume = "17",
pages = "47--50",
journal = "CLIN TRANSL RAD ONCO",
issn = "2405-6308",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - The failure of cetuximab-based de-intensified regimes for HPV-positive OPSCC: A radiobiologists perspective

AU - Rieckmann, Thorsten

AU - Kriegs, Malte

PY - 2019/7

Y1 - 2019/7

N2 - Human Papillomavirus-positive oropharyngeal cancer is a rising tumor entity with unique characteristics and favorable prognosis. Because current multimodal therapies are associated with severe toxicity, different strategies for treatment de-intensification are being tested in clinical trials. In this context two phase 3 studies, which examined the potential of the monoclonal anti-EGFR antibody cetuximab to replace concomitant cisplatin-based chemotherapy, have concordantly reported inferiority of this de-intensification approach. In this opinion article we discuss these recent negative results in the light of previous clinical and preclinical research on the combination of EGFR-inhibition and irradiation. Collectively these data question the effectiveness of EGFR-inhibition in the curative treatment of both HPV-positive and HPV-negative head and neck cancer but provide guidance for future translational research.

AB - Human Papillomavirus-positive oropharyngeal cancer is a rising tumor entity with unique characteristics and favorable prognosis. Because current multimodal therapies are associated with severe toxicity, different strategies for treatment de-intensification are being tested in clinical trials. In this context two phase 3 studies, which examined the potential of the monoclonal anti-EGFR antibody cetuximab to replace concomitant cisplatin-based chemotherapy, have concordantly reported inferiority of this de-intensification approach. In this opinion article we discuss these recent negative results in the light of previous clinical and preclinical research on the combination of EGFR-inhibition and irradiation. Collectively these data question the effectiveness of EGFR-inhibition in the curative treatment of both HPV-positive and HPV-negative head and neck cancer but provide guidance for future translational research.

U2 - 10.1016/j.ctro.2019.05.003

DO - 10.1016/j.ctro.2019.05.003

M3 - SCORING: Journal article

C2 - 31206086

VL - 17

SP - 47

EP - 50

JO - CLIN TRANSL RAD ONCO

JF - CLIN TRANSL RAD ONCO

SN - 2405-6308

ER -